Fig. 4From: Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapyBTLA/HVEM axis as a target for cancer immunotherapy. Multiple approaches are being developed at pre-clinical and clinical levels, including monoclonal antibodies (in monotherapy or combination with anti-PD-1 or chemotherapeutic agents) and sHVEM-producing CAR-T cellsBack to article page